Nov 3, 2021 | Business
JSP Pharmaceutical Manufacturing (Thailand) PCL (SET: JP), a developer, manufacturer and distributor of modern and traditional medicines, herbal products and nutritional supplements, is debuting on the MAI today. JSP is ready to pursue growth through developing new products under own brands, aiming for higher profit margins by boosting own brand sales to 50% of total sales of all products, while increasing capacity, improving capital management efficiency, expanding OEM production, and ultimately leading in the R&D, production and distribution of medicines and nutritional supplements.
Dr. Sittichai Daengprasert, Chief Executive Officer of JSP Pharmaceutical Manufacturing (Thailand) PCL, whose shares will begin trading on the SET Market of Alternative Investment (MAI) today in the Consumer Products sector under the symbol JP, says it is a crucial step for the company to pursue sustainable growth in order to become a leader in the R&D, manufacture and distribution of medicinal and nutritional supplement products in Thailand. It plans to drive growth with innovations in the development of modern and traditional medicines, and herbal and nutritional supplement products to satisfy consumers’ demand for high-quality products for health maintenance, protection and treatment. The plan will lend support to Thailand’s effort to become a society of health care in the near future.
Dr. Sittichai says the proceeds from the IPO share sales will go toward the development of new health products under the company’s own brands with a goal to produce 4-5 new products each year. Meanwhile, a multi-channel marketing strategy will be employed for product distribution, encompassing pharmacies, modern trade stores, convenience stores, TV home shopping, and online channels. The aim is to boost sales of own-brand products to 50% of total sales, which will contribute positively to the gross profit in the future.
Plans to improve the efficiency of the Bangkok plant, a hub of modern medicine production, and expand the capacity of the plant in Lamphun, which produces traditional medicines and nutritional supplements, will support the expansion of the OEM customer base in Thailand and in the CLMV countries with a one-stop service. Equipped with a list of more than 2,000 registered medicines, JP is in an advantageous position to meet OEM customers’ demands, Dr. Sittichai says.
He adds that the company has also been cooperating with educational institutes, government agencies and private-sector parties in the development and processing of herbs, such as Wolffia globosa, as a plant-based protein supplement under the ‘Suphap Osot’ brand to add value to agricultural products. In this program, cultivation know-how is transferred to farmers as a way to help them earn increased income. Furthermore, JP is preparing its manufacturing base to produce extracts from cannabis and hemp. These extracts are to be sold as processed products or used as ingredients in health products under the company’s own brands.
Mr. Vorachart Tuaychareon, Managing Director of Finnex Advisory Co., Ltd., a financial advisor, says JP’s potential for growth looks bright amid positive factors resulting from increasing demands for modern and herbal medicines from health-conscious consumers while the government sector encourages people to consume locally-made medicinal products. The company’s extensive experience and expertise in the R&D of diverse medicinal products and its experienced executives’ ceaseless pursuit of business opportunities are sure to improve its competitiveness and growth prospects.
Mr. Chosit Detwanitchayanumut, Managing Director of Siam Alpha Capital Co., Ltd., a joint financial advisor, says JP is determined to strengthen its operations in all respects by highlighting product innovations and investing in marketing campaigns to increase public awareness of its own brands as well as expand its OEM customer base both here and abroad. The company’s strong fundamentals lend firm support for its drive toward a sustainable growth, he adds.
Mr. Chanachai Joonjiraporn, Chief Executive Officer, ASL Securities Co., Ltd., the lead underwriter, says JP’s shares are growth stock because of the strength of its operations. Its commitment to pursue long-term and sustainable growth lays a firm foundation on which its shares are grounded and is the reason that will attract sustained investors’ interest in JP’s shares.
Released by Public Relations Dept., MT Multimedia Co. Ltd.
for JSP Pharmaceutical Manufacturing (Thailand) PCL
For more information, please contact: Yuttachai Praikhanahok (Tle)
Tel: +66-91-736-2866 or +66-2-612-2081 ext 125
Email: yuttachai.p@mtmultimedia.com
Topic: IPO
Jul 21, 2021 | Business
Almost half of the respondents, around 46.6%, believed that their own companies fell behind the industry average when it comes to utilising digital tools as part of business processes, according to a survey conducted by AIBP and Oracle from March to April. The survey counted 193 professionals*, mainly from IT, innovation & business backgrounds in manufacturing and supply chain companies across the largest economies in Southeast Asia: Singapore, Indonesia, Malaysia, Thailand, Philippines & Vietnam.
The manufacturing industry plays a significant role in local economies of Southeast Asian countries, contributing more than 20% of Gross Domestic Products in markets like Singapore, Indonesia, Malaysia and Thailand. Recent US-China trade tensions have also increased expectations of how manufacturing can contribute to markets like Indonesia and Vietnam. Concurrently, local governments are focused on uplifting local manufacturing capabilities by implementing policies to encourage and support initiatives towards Industry 4.0
The survey also found that 46.6% of respondents believed that the top priority of implementing digital solutions should be to drive operational efficiency in a bid to reduce costs, while 16.6% feel that it should be used to increase or create revenue opportunities.
The COVID-19 pandemic has seen supply chain disruptions across industries – while some companies struggled to come to terms with unusual fluctuations in supply and demand, other companies were better prepared. Thossaporn Petporee, SVP and part of Charoen Pokphand Foods digital committee outlined how Charoen Pokphand Foods have been ahead of the curve when it comes to digital transformation because of their experiences navigating past disruptions like the African swine fever and Avian Influenza. “Each time a pandemic hit, we prepared ourselves better. In our farms, we have the highest level of biosecurity and AI to identify animals across the farm and sales areas. We do well because we keep up to date, keep challenging ourselves.” The recent pandemic has led them to develop innovative online solutions like Vet Online and chatbots which are made available to the farms across their network to allow for diagnosis of animal diseases remotely. Charoen Pokphand Foods saw a net profit increase of 41% in 2020.
Companies from the Manufacturing and Supply Chain industries continue to innovate. In 2020, 3 out of 10 winners of the annual ASEAN Enterprise Innovation Awards were from the Manufacturing and Supply Chain industries, including Kalbe Farma and Astra International. Both companies embarked on digital transformation projects which involved integration of their ERP across business units to allow for a more connected supply chains; enabling real time feedback from across the entire value chain.
“There is an urgent need to reorganize one’s supply chains in the wake of 2020 and the recent Suez Canal blockage, and manufacturers in the region are rightly realising that what they have in-house is not enough when creating robust and resilient logistics processes that keep the business moving efficiently,” said Michael Lim, GTM Leader, ERP & Digital Supply Chain, Oracle. “With new capabilities upgraded onto Oracle Fusion Cloud Supply Chain Management each quarter, we are helping our customers streamline logistics to fulfil orders faster, cheaper and more sustainably to deliver the operational excellence they desire.”
*The survey was sent to professionals working in 1,600 publicly listed companies and/or subsidiaries of MNCs in Indonesia, Malaysia, Thailand, Philippines, Vietnam & Singapore. These companies represent the following sectors: Consumer Durables, Non-Durables, Electronic Technology, Process Industries & Producer Manufacturing.
About AIBP
AIBP serves as an avenue for public and private organisations in Southeast Asia to access and exchange information about growth and innovation within the B2B space. With a current network of over 30,000 stakeholders in Southeast Asia, AIBP continues to develop ecosystems by engaging in activities which create value-adding information for our stakeholders seeking to make transformative impacts within their organisations. AIBP is a business unit of Industry Platform, a growth consulting firm based in Singapore.
About Industry Platform Pte Ltd
We work with public and private organisations to develop value-adding partnerships within the industries and markets which we serve. Our consulting framework advocates pursuing an integrated approach in assisting our clients in their growth and development initiatives. This includes market research, and access through business development strategy formulation and execution.
Topic: Press release summary
Contact